WHO TESTS THE MEDICINES INDIA MAKES?

 

BIZ MASALA SIGNATURE STORY

Inside the business of pharmaceutical testing laboratories — the money, the market and the science behind a medicine’s quality

By Murthy ASR  |  18 October 2026

Illustrative editorial image: pharmaceutical analytical testing laboratory.

A medicine may be manufactured on a modern production line, packed in a clean facility and shipped across the world. But before a batch can be trusted, its quality has to be demonstrated. Behind that assurance is a less visible industry: laboratories that test ingredients, finished formulations, impurities, stability and, where relevant, biological characteristics.

For India, this is more than a technical service. The country’s pharmaceutical manufacturers supply domestic patients and regulated markets overseas. Their products must meet specifications, documentation requirements and regulatory expectations that vary by medicine and destination. Testing laboratories help generate the evidence on which quality decisions depend.

The business question is increasingly important: as medicines become more complex and regulatory expectations rise, can independent laboratories build a larger, higher-value role in the pharmaceutical supply chain?

A market growing — but what exactly are we measuring?

Grand View Research estimates that India’s pharmaceutical analytical testing outsourcing market could reach US$417.4 million by 2033, with a projected compound annual growth rate of 10.5% over 2026–2033. This is a forecast for a defined outsourcing segment, not the value of every drug-testing activity in India. Market estimates depend on how analysts define services, customers and market boundaries.

Source: Grand View Research, India pharmaceutical analytical testing outsourcing market outlook. Forecast, not audited industry revenue.

The underlying commercial logic is straightforward. Building an in-house laboratory requires expensive instruments, specialist staff, validated methods, quality systems and ongoing maintenance. Outsourcing can give a drugmaker access to specialised equipment and expertise without replicating every capability internally. For the laboratory, however, the model works only if it can attract repeat work, maintain quality and use its capacity efficiently.

This is not a simple commodity business. Routine tests may compete on price and turnaround time. Complex impurity analysis, method development, stability studies and testing for biologics can demand deeper scientific expertise and more sophisticated infrastructure.

What does a pharmaceutical testing laboratory actually do?

Illustrative view of analytical laboratory equipment; not a photograph of a named company.

Service area	What it can establish	Why customers need it
Raw-material and finished-product testing	Whether a sample meets specified identity, strength, purity and other quality criteria	Batch release, supplier qualification and routine quality control
Stability studies	How product quality changes under defined storage conditions over time	Shelf-life assessment and regulatory documentation
Impurity profiling	Presence and levels of specified or unexpected impurities, within the method’s capability	Product development, process control and risk management
Method development and validation	Whether an analytical method is suitable for its intended purpose	Reliable, reproducible testing and support for regulatory submissions
Microbiology and specialised testing	Microbial limits, sterility-related attributes or other product-specific measures, as applicable	Testing requirements depend on dosage form, product and regulations

 

The required tests differ by product. A tablet, injectable medicine, vaccine, medical device and biologic do not share one universal testing checklist. Nor does one laboratory accreditation automatically prove that every service, method or facility is approved for every regulatory purpose.

Who is in the market?

The competitive landscape spans listed Indian laboratory businesses, international testing groups, contract research organisations, specialist private laboratories and government drug-testing facilities. They overlap in some services but should not be treated as interchangeable.

Player / category	Position in the ecosystem	What our research should examine
Vimta Labs	Listed Indian testing and research services company with laboratory operations across multiple sectors	Pharma-related service mix, growth, margins, capacity investment and customer concentration
SGS	International testing, inspection and certification group	Pharmaceutical testing capabilities, India footprint and global client relationships
Eurofins Scientific	International laboratory-services group	Specialised testing portfolio, scale and competition with Indian providers
Cotecna / Energon Labs	Cotecna announced its acquisition of Hyderabad-based Energon Labs on 16 October 2026	How the acquisition expands life-sciences testing capabilities and India presence
Government drug-testing laboratories	Statutory testing infrastructure under drug regulators	Public oversight, sample testing, enforcement support and laboratory capacity
Other CROs and independent laboratories	Providers of analytical, bioanalytical, stability and related services	Specialisation, accreditations, export-market readiness and commercial economics

 

This is a representative map, not a league table. The companies’ overall revenues are not directly comparable because some earn substantial income from food, environmental, consumer-product, clinical or other testing services in addition to pharmaceuticals.

The listed-company lens: Vimta’s numbers

Vimta Labs’ FY2024–25 annual report offers a useful financial window into a listed laboratory-services business. It reported revenue from operations of ₹3,439.82 million in FY2024–25, up from ₹2,885.95 million in FY2023–24. Profit before tax rose to ₹890.00 million from ₹625.04 million. These are company-wide figures, not pharmaceutical-testing revenue alone.

Source: Vimta Labs Limited, Annual Report 2024–25. Figures shown are revenue from operations; they do not isolate pharmaceutical testing.

Vimta Labs financial indicator	FY2023–24	FY2024–25
Revenue from operations	₹2,885.95 million	₹3,439.82 million
Profit before tax	₹625.04 million	₹890.00 million
Total income	₹2,923.05 million	₹3,482.22 million

 

The figures suggest a growing business and improving pre-tax performance during the period. They do not, by themselves, prove that pharmaceutical testing was the principal growth driver. A sharper company comparison would require segment disclosures, service-line detail and comparable data from peers.

The other side of the story: public oversight

Illustrative editorial image of a scientist at work.

Commercial laboratories paid by manufacturers and government drug-testing laboratories perform different roles. The Central Drugs Standard Control Organisation’s laboratory network tests drug samples for regulatory purposes, including samples of imported drugs and products referred by central and state drug-control authorities. The official laboratory pages also describe roles such as analysis of survey samples and support for regulatory functions.

The distinction matters. Contract laboratories help clients meet product-development, quality-control and regulatory needs. Statutory laboratories support public oversight. A test report from one setting should not casually be described as equivalent to a regulator’s independent finding in another.

The commercial model also depends on trust in data. Laboratories need controlled procedures, suitable methods, trained analysts, instrument maintenance, documented investigations and reliable records. Where results are used in regulatory submissions or product-release decisions, a quality-system failure can have consequences beyond the laboratory’s immediate customer relationship.

Where the next wave of growth may come from

Potential growth driver	Business opportunity	What could limit it
More outsourcing	Manufacturers use external expertise rather than duplicate every capability	Price pressure, client bargaining power and utilisation swings
Complex medicines and biologics	Demand for specialised characterisation and testing	High equipment costs, technical complexity and long qualification cycles
Export-oriented manufacturing	Testing packages aligned with multiple market requirements	Regulatory differences, audit demands and customer concentration
Acquisitions and networks	Access to new clients, specialist capabilities and geography	Integration risk, culture, quality-system harmonisation and purchase price
Digital laboratory systems	Better traceability, audit trails and workflow management	Implementation cost and the need to protect data integrity

 

Hyderabad is a natural geography to watch because it has a substantial pharmaceutical and life-sciences ecosystem. Cotecna’s October 2026 announcement that it acquired Energon Labs illustrates how an international testing group can seek to deepen its capabilities through a Hyderabad laboratory. The transaction announcement identifies Energon’s services and certifications, but it does not disclose a purchase price or establish the financial contribution the acquired business will make. Those questions require further reporting.

The unanswered questions for investors and the industry

The most useful measure of a testing laboratory is not simply how many instruments it owns or how quickly it can expand. The economics depend on how often its equipment is used, the price and complexity of the tests, staff productivity, repeat customer demand, compliance costs and the time required to qualify new services with clients.

For investors, the next questions are whether revenue growth converts into cash flow, whether margins are sustainable, how much capital must be reinvested, and whether acquisitions earn an adequate return. For drugmakers, the questions are reliability, turnaround, technical competence and the credibility of the data. For patients, the ultimate concern is whether medicines meet the quality standards they are supposed to meet.

Biz Masala takeaway

India’s pharmaceutical testing laboratories operate at the intersection of science, regulation and business. The outsourcing market has room to grow, but its value cannot be judged by a single headline forecast or by combining the total revenues of companies with very different service mixes. The winners are likely to be laboratories that pair technical capability with consistent quality, credible data, efficient operations and customer trust.

The next step is a deeper industry investigation: compare listed-company financials, map specialist providers in Hyderabad and elsewhere, track laboratory acquisitions, and examine what public records reveal about capacity and regulatory oversight. That is where the industry story moves from market promise to evidence.

Sources and editorial notes

·       Grand View Research, India Pharmaceutical Analytical Testing Outsourcing Market Outlook, 2033: https://www.grandviewresearch.com/horizon/outlook/pharmaceutical-analytical-testing-outsourcing-market/india

·       Vimta Labs Limited, Annual Report 2024–25: https://vimta.com/wp-content/uploads/2.-Annual_Report_2024_25.pdf

·       CDSCO, Central Drug Testing Laboratories: https://www.cdsco.gov.in/opencms/opencms/en/About-us/Laboratories/

·       Cotecna, “Cotecna Group Acquires Energon Labs”, 16 October 2026: https://www.cotecna.com/en/media/news/cotecna-group-acquires-energon-labs

·       Grand View Research, global Pharmaceutical Analytical Testing Outsourcing Market, 2026–2033: https://www.grandviewresearch.com/industry-analysis/pharmaceutical-analytical-testing-outsourcing-market

Editorial note: Market-size figures are third-party estimates and forecasts, not audited industry totals. Company financials are consolidated company-wide figures unless explicitly identified otherwise. Images are illustrative, not photographs of named laboratories. This story does not allege misconduct by any company or laboratory.

BIZ MASALA